Is Syneos Health, Inc. overvalued or undervalued?

As of 1 October 2023, Syneos Health, Inc. moved from fair to attractive. The company is currently undervalued. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 2.3, and a Return on Equity (ROE) of 12.5%. In comparison, peers such as ICON plc have a P/E of 18.5, while PRA Health Sciences shows a P/B of 3.0, indicating that Syneos Health is trading at a discount relative to its industry counterparts.
Additionally, Syneos Health's stock has shown resilience, outperforming the Sensex in recent months, which supports the argument for its undervaluation. Overall, the combination of favorable ratios and peer comparisons suggests that Syneos Health presents a compelling investment opportunity at its current valuation.